Determinación de la dosis eritemática mínima y reacciones anómalas a radiación ultravioleta A según fototipo / Determination of Minimal Erythema Dose and Anomalous Reactions to UVA Radiation by Skin Phototype

ANTECEDENTES: La técnica del fototest evalúa la sensibilidad de la piel a la radiación ultravioleta (RUV) mediante la determinación de la mínima dosis de radiación capaz de producir eritema (dosis mínima eritemática [DEM]) y la respuesta anómala a UVA. No existen guías protocolizadas para la técnica del fototest. METODOLOGÍA: Estudio multicéntrico de cohortes prospectivo. Un total de 232 voluntarios sanos fueron reclutados en 9 centros hospitalarios. El fototest se realizó con simuladores solares (SS) o lámparas fluorescentes de UVB de banda ancha (UVBBA). Cada sujeto recibió un total de 5 o 6 dosis progresivas de radiación eritemática y 4 dosis de UVA. La lectura se realizó a las 24 h. RESULTADOS: La DEM media por fototipo fue de 23 ± 8, 28 ± 4, 35 ± 4 y 51 ± 6 mJ/cm2 (fototipos I a IV respectivamente) para los centros que utilizaron SS y de 28 ± 5, 32 ± 3 y 34 ± 5 mJ/cm2 cuando se utilizaron lámparas de UVBBA para fototipos del II al IV. Se consideraron valores de DEM patológica 7, 19, 27 y 38 mJ/cm2, para los fototipos I al IV respectivamente cuando se emplearon SS y de 18, 24 y 24 mJ/cm2 para los fototipos II-IV expuestos a lámparas de UVBBA. A dosis de hasta 20 J/cm2 de UVA no se observaron respuestas anómalas. CONCLUSIONES: Existe homogeneidad de resultados en los diferentes centros participantes, lo que permite estandarizar el método del fotodiagnóstico para los diferentes fototipos cutáneos, así como establecer las dosis umbral que definen una respuesta anómala a la radiación ultravioleta

BACKGROUND: Phototesting is a technique that assesses the skin's sensitivity to UV radiation by determining the smallest dose of radiation capable of inducing erythema (minimal erythema dose [MED]) and anomalous responses to UV-A radiation. No phototesting protocol guidelines have been published to date. METHODOLOGY: This was a multicenter prospective cohort study in which 232 healthy volunteers were recruited at 9 hospitals. Phototests were carried out with solar simulators or fluorescent broadband UV-B lamps. Each individual received a total of 5 or 6 incremental doses of erythemal radiation and 4 doses of UV-A radiation. The results were read at 24 hours. RESULTS: At hospitals where solar simulators were used, the mean (SD) MED values were 23 (8), 28 (4), 35 (4), and 51 (6) mJ/cm2 for skin phototypes I to IV, respectively. At hospitals where broadband UV-B lamps were used, these values were 28 (5), 32 (3), and 34 (5) mJ/cm2 for phototypes II to IV, respectively. MED values lower than 7, 19, 27, and 38 mJ/cm2 obtained with solar simulators were considered to indicate a pathologic response for phototypes I to IV, respectively. MED values lower than 18, 24, and 24 mJ/cm2 obtained with broadband UV-B lamps were considered to indicate a pathologic response for phototypes II to IV, respectively. No anomalous responses were observed at UV-A radiation doses of up to 20 J/cm2. CONCLUSIONS: Results were homogeneous across centers, making it possible to standardize diagnostic phototesting for the various skin phototypes and establish threshold doses that define anomalous responses to UV radiation

Leishmaniasis cutánea en un paciente con artritis psoriásica tratado con infliximab: tratamiento con crioterapia y Glucantime® intralesional / Cutaneous Leishmaniasis in a Patient Receiving Infliximab for Psoriatic Arthritis: Treatment with Cryotherapy and Intralesional Meglumine Antimonate

No disponible

Anetodermia primaria asociada a síndrome de Sjögren primario y anticuerpos anticardiolipina / Primary Anetoderma Associated With Primary Sjögren Syndrome and Anticardiolipin Antibodies

No disponible

Hematopoyesis extramedular cutánea en mielofibrosis idiopática: a propósito de un caso / A case of cutaneous extramedullary hematopoiesis associated with idiopathic myelofibrosis

La hematopoyesis extramedular cutánea es una manifestación infrecuente de los procesos mieloproliferativos crónicos, principalmente de la mielofibrosis crónica idiopática. En el adulto se manifiesta como máculas, pápulas, nódulos y úlceras en el tronco. La aparición suele darse poco después del diagnóstico y todavía es una cuestión debatida la posible relación entre la esplenectomía y la aparición de los focos de hematopoyesis extramedular. El diagnóstico se realiza mediante estudio histopatológico y la visualización de un infiltrado compuesto por diferentes combinaciones de precursores mieloides, eritroides y células megacariocíticas. El tratamiento es sintomático y el propio de la enfermedad de base. Aportamos un nuevo caso asociado a mielofibrosis crónica idiopática que a los 9 años del diagnóstico presentó focos de hematopoyesis extramedular cutánea. Dichas lesiones siguieron un curso progresivo, desarrollando posteriormente una leucemia mieloide aguda (AU)

Cutaneous extramedullary hematopoiesis is a rare manifestation of chronic myeloproliferative processes, mainly chronic idiopathic myelofibrosis. In adults, it manifests as macules, papules, nodules, and ulcers on the trunk. The lesions usually appear soon after diagnosis and the possibility of a relationship between splenectomy and the appearance of extramedullary foci of hematopoiesis is still debated. Diagnosis is based on histopathology showing an infiltrate with different combinations of myeloid and erythroid cell precursors and megakaryocytes. Symptomatic treatment is provided alongside treatment of the underlying disease. We report a new case associated with chronic idiopathic myelofibrosis in which foci of cutaneous extramedullary hematopoiesis were observed 9 years after initial diagnosis. The lesions were progressive and the patient went on to develop acute myeloid leukemia (AU)

Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature.

Paraneoplastic pemphigus (PNP) is an autoimmune blistering disease with poor prognosis when associated with malignant neoplasm. We report the case of a patient with PNP associated with a CD20+ non-Hodgkin follicular lymphoma who was treated with Rituximab plus corticosteroids and short courses of cyclosporin. One and a half years after Rituximab therapy, oral ulcerations had cleared and oral methylprednisolone was slowly tapered down without further recurrences. In the course of the disease, the patient developed sepsis due to Listeria monocytogenes and viral infections by human herpes virus 1 and 3. At the end-stage of the disease she developed a cutaneous infection from Mycobacterium chelonae. The patient died 2 years and 7 months after the onset of PNP. Rituximab may be useful for PNP therapy, but further studies are necessary to confirm this hypothesis.